Dianthus Therapeutics, Inc.
DNTH
$16.86
-$0.585-3.35%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -29.51M | -28.44M | -25.17M | -17.61M | -13.75M |
Total Depreciation and Amortization | 133.00K | 78.00K | 289.00K | -62.00K | 107.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 3.41M | 1.34M | 1.02M | 2.85M | 1.52M |
Change in Net Operating Assets | -1.66M | -422.00K | 2.60M | 289.00K | -2.82M |
Cash from Operations | -27.63M | -27.44M | -21.27M | -14.53M | -14.94M |
Capital Expenditure | -24.00K | -31.00K | -25.00K | -17.00K | -32.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 14.82M | -23.08M | -259.34M | 1.19M | -5.48M |
Cash from Investing | 14.79M | -23.11M | -259.36M | 1.17M | -5.51M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 161.00K | 39.68M | 296.00K | 47.00K | 230.27M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 0.00 | 0.00 | -2.24M | -12.42M |
Cash from Financing | 161.00K | 39.68M | 296.00K | -2.20M | 217.85M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -12.68M | -10.88M | -280.34M | -15.56M | 197.40M |